Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis.
Okano T, Kobayashi T, Yasuma T, D'Alessandro-Gabazza CN, Toda M, Fujimoto H, Nakahara H, Okano Y, Takeshita A, Nishihama K, Saiki H, Tomaru A, Fridman D'Alessandro V, Ishida S, Sugimoto H, Takei Y, Gabazza EC.
Okano T, et al. Among authors: okano y.
Front Pharmacol. 2020 Nov 27;11:593620. doi: 10.3389/fphar.2020.593620. eCollection 2020.
Front Pharmacol. 2020.
PMID: 33390975
Free PMC article.